Company news

Halozyme Therapeutics, Inc. news in 2023

Halozyme Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Halozyme Announces argenx Receives European Commission Approval of VYVGART® SC with ENHANZE® for Generalized Myasthenia Gravis

November 15, 2023

Halozyme reports third quarter 2023 financial and operating results

November 5, 2023

Halozyme and Acumen Pharmaceuticals Enter Global Collaboration and Non-Exclusive License Agreement for the ENHANZE® Technology in Alzheimer's Disease

November 5, 2023

Halozyme To Report Third Quarter 2023 Financial and Operating Results

October 29, 2023

Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma

October 18, 2023

Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference

October 15, 2023

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

October 15, 2023

Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

August 28, 2023

Halozyme reports second quarter 2023 financial and operating results

August 7, 2023

Halozyme To Report Second Quarter 2023 Financial and Operating Results

July 24, 2023

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

July 16, 2023

Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

July 12, 2023

Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis

June 19, 2023

Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

June 5, 2023

Halozyme reports first quarter 2023 financial and operating results

May 8, 2023

Halozyme To Report First Quarter 2023 Financial and Operating Results

April 24, 2023

Halozyme reports fourth quarter and full year 2022 financial and operating results

February 20, 2023

Halozyme to Report Fourth Quarter and Full Year 2022 Financial and Operating Results

February 6, 2023

Halozyme Appoints Barbara Duncan to its Board of Directors

February 5, 2023

Halozyme Therapeutics, Inc. announces redemption of 1.25% convertible senior notes due 2024

January 10, 2023

Halozyme Provides 2023 Financial Guidance and Outlook

January 9, 2023

Halozyme to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

Calls in 2023

Decks in 2023